Cargando…

Clinical features and mechanistic insights into drug repurposing for combating COVID-19

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged from Wuhan in China before it spread to the entire globe. It causes coronavirus disease of 2019 (COVID-19) where mostly individuals present mild symptoms, some remain asymptomatic and some show severe lung inflammation and pneumoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Asrani, Purva, Tiwari, Keshav, Eapen, Mathew Suji, McAlinden, Kielan Darcy, Haug, Greg, Johansen, Matt D., Hansbro, Philip M., Flanagan, Katie L., Hassan, Md. Imtaiyaz, Sohal, Sukhwinder Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570392/
https://www.ncbi.nlm.nih.gov/pubmed/34748991
http://dx.doi.org/10.1016/j.biocel.2021.106114
_version_ 1784594829168082944
author Asrani, Purva
Tiwari, Keshav
Eapen, Mathew Suji
McAlinden, Kielan Darcy
Haug, Greg
Johansen, Matt D.
Hansbro, Philip M.
Flanagan, Katie L.
Hassan, Md. Imtaiyaz
Sohal, Sukhwinder Singh
author_facet Asrani, Purva
Tiwari, Keshav
Eapen, Mathew Suji
McAlinden, Kielan Darcy
Haug, Greg
Johansen, Matt D.
Hansbro, Philip M.
Flanagan, Katie L.
Hassan, Md. Imtaiyaz
Sohal, Sukhwinder Singh
author_sort Asrani, Purva
collection PubMed
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged from Wuhan in China before it spread to the entire globe. It causes coronavirus disease of 2019 (COVID-19) where mostly individuals present mild symptoms, some remain asymptomatic and some show severe lung inflammation and pneumonia in the host through the induction of a marked inflammatory ‘cytokine storm’. New and efficacious vaccines have been developed and put into clinical practice in record time, however, there is a still a need for effective treatments for those who are not vaccinated or remain susceptible to emerging SARS-CoV-2 variant strains. Despite this, effective therapeutic interventions against COVID-19 remain elusive. Here, we have reviewed potential drugs for COVID-19 classified on the basis of their mode of action. The mechanisms of action of each are discussed in detail to highlight the therapeutic targets that may help in reducing the global pandemic. The review was done up to July 2021 and the data was assessed through the official websites of WHO and CDC for collecting the information on the clinical trials. Moreover, the recent research papers were also assessed for the relevant data. The search was mainly based on keywords like Coronavirus, SARS-CoV-2, drugs (specific name of the drugs), COVID-19, clinical efficiency, safety profile, side-effects etc.This review outlines potential areas for future research into COVID-19 treatment strategies.
format Online
Article
Text
id pubmed-8570392
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-85703922021-11-05 Clinical features and mechanistic insights into drug repurposing for combating COVID-19 Asrani, Purva Tiwari, Keshav Eapen, Mathew Suji McAlinden, Kielan Darcy Haug, Greg Johansen, Matt D. Hansbro, Philip M. Flanagan, Katie L. Hassan, Md. Imtaiyaz Sohal, Sukhwinder Singh Int J Biochem Cell Biol Review Article Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged from Wuhan in China before it spread to the entire globe. It causes coronavirus disease of 2019 (COVID-19) where mostly individuals present mild symptoms, some remain asymptomatic and some show severe lung inflammation and pneumonia in the host through the induction of a marked inflammatory ‘cytokine storm’. New and efficacious vaccines have been developed and put into clinical practice in record time, however, there is a still a need for effective treatments for those who are not vaccinated or remain susceptible to emerging SARS-CoV-2 variant strains. Despite this, effective therapeutic interventions against COVID-19 remain elusive. Here, we have reviewed potential drugs for COVID-19 classified on the basis of their mode of action. The mechanisms of action of each are discussed in detail to highlight the therapeutic targets that may help in reducing the global pandemic. The review was done up to July 2021 and the data was assessed through the official websites of WHO and CDC for collecting the information on the clinical trials. Moreover, the recent research papers were also assessed for the relevant data. The search was mainly based on keywords like Coronavirus, SARS-CoV-2, drugs (specific name of the drugs), COVID-19, clinical efficiency, safety profile, side-effects etc.This review outlines potential areas for future research into COVID-19 treatment strategies. Elsevier Ltd. 2022-01 2021-11-05 /pmc/articles/PMC8570392/ /pubmed/34748991 http://dx.doi.org/10.1016/j.biocel.2021.106114 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Asrani, Purva
Tiwari, Keshav
Eapen, Mathew Suji
McAlinden, Kielan Darcy
Haug, Greg
Johansen, Matt D.
Hansbro, Philip M.
Flanagan, Katie L.
Hassan, Md. Imtaiyaz
Sohal, Sukhwinder Singh
Clinical features and mechanistic insights into drug repurposing for combating COVID-19
title Clinical features and mechanistic insights into drug repurposing for combating COVID-19
title_full Clinical features and mechanistic insights into drug repurposing for combating COVID-19
title_fullStr Clinical features and mechanistic insights into drug repurposing for combating COVID-19
title_full_unstemmed Clinical features and mechanistic insights into drug repurposing for combating COVID-19
title_short Clinical features and mechanistic insights into drug repurposing for combating COVID-19
title_sort clinical features and mechanistic insights into drug repurposing for combating covid-19
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570392/
https://www.ncbi.nlm.nih.gov/pubmed/34748991
http://dx.doi.org/10.1016/j.biocel.2021.106114
work_keys_str_mv AT asranipurva clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT tiwarikeshav clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT eapenmathewsuji clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT mcalindenkielandarcy clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT hauggreg clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT johansenmattd clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT hansbrophilipm clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT flanagankatiel clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT hassanmdimtaiyaz clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19
AT sohalsukhwindersingh clinicalfeaturesandmechanisticinsightsintodrugrepurposingforcombatingcovid19